Topic summary

Oral semaglutide bioavailability and its variability between people

Compounds › Oral incretins SOUL trial oral semaglutide randomised trial

This is a generated summary. It shows the 7 most-liked posts from a topic of 49, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

integrator_traceTL2Member4 Sep 2025#3

s.hartmann, post #1: Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is… Go to post

Picking up post #2: that is the part I would want checked first.

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

25 likes in reply to #1 11mo

LeitermanTL3Regular25 Oct 2025#11

Coming back to post #9, because the follow-up matters more than the original answer.

Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.

29 likes 9mo

j.habermannTL3Regular15 Nov 2025 · edited#15

SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.

21 likes 8mo

j.ivaturiTL2 Moderator10 Dec 2025#20

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

28 likes 8mo

m.ekstromTL2 Moderator20 Dec 2025#22

26 likes 7mo

a.eriksenTL2 Moderator28 Feb 2026#38

ne.laurent, post #8: I read post #6 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.

24 likes in reply to #8 5mo

n.norgaardTL2 Moderator29 Mar 2026#45

20 likes 4mo

Read the full topic (49 posts)

This topic was referenced in

About the Oral incretins categoryCompounds › Oral incretins · 4 replies
Why fasting instructions for oral semaglutide are not optional adviceCompounds › Oral incretins · 74 replies
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomesCompounds › Oral incretins · 104 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
Why oral semaglutide needs an absorption enhancer at all Compounds › Oral incretins randomised trial orforglipron oral semaglutide SOUL trial Solved Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…	+59	65	61k	7mo
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…	+11	15	17k	24d
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…	+19	23	332	8mo

Related topics — sharing the tags SOUL trial, oral semaglutide, randomised trial

Topic	Participants	Replies	Views	Activity
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…	+11	15	17k	24d
Food effects on oral incretin absorption: what is documented Compounds › Oral incretins PIONEER programme SOUL trial randomised trial oral semaglutide Solved Under review On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		2	4.4k	12mo
Primary endpoint hierarchies and why order matters — one year on Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial Solved On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-2 ( N Engl J Med ,…	+56	61	37k	11h
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…	+19	23	332	8mo